Gerri Henwood
President/Founder
Ms. Henwood is the President/Founder of Malvern Consulting Group and is the President/CEO of Recro Pharma. She was the President and CEO of Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL), a company she founded in late 1999. She raised $90 million in private equity and was able to take the company public in August 2004. As of December 31, 2009, Auxilium's market capitalization exceeded $1.3 billion. Ms. Henwood successfully shepherded this start-up company through the drug development stage to its current position with one drug on the market and several more in late stage development and trailing 12 month revenues exceeding $60 million.

From 1985-1999, Ms. Henwood was the founder and CEO of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998.

Ms. Henwood began her career with Smith Kline & French, now part of Glaxo SmithKline PLC, in the pharmaceutical marketing department. She rose through the ranks at Smith Kline & French to be the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director – Marketing in the International Pharmaceutical Division.

Ms. Henwood currently serves on the Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), Garnet BioTherapeutics, Inc. (private), LZ Therapeutics, Inc. (private), MAP Pharmaceuticals, Inc. (private) and is a member of the Board of Trustees for LaSalle Academy, an elementary school for "at risk" youth, in Philadelphia, PA. Ms. Henwood holds a B.S. degree from Neumann College.

Randy Mack
Executive Vice President, Development
Mr. Mack currently serves as the Executive Vice President, Development for Malvern Consulting Group. Previously, he served as Vice President, Project Management and Operations at Adolor Corporation where he oversaw the development programs in the areas of opioid-induced bowel dysfunction and pain management. For more than 15 years he has also held positions of increasing responsibilities at Auxilium Pharmaceuticals, Abbott Laboratories and Harris Laboratories. In these positions he was responsible for the conduct of over 400 clinical trials, filing of 20 INDs and 4 NDAs. During his career he has authored more than 75 scientific articles, book chapters, abstracts and poster presentations in the areas of gastroenterology, urology, neuroscience and psychiatric disorders. Mr. Mack holds a BS in biology and chemistry from the University of Nebraska-Lincoln.

Diane Myers
Senior Vice President, Regulatory Affairs & Quality Assurance
Ms. Myers joined Malvern Consulting Group in October 2008 as Senior Vice President of Regulatory Affairs and Quality Assurance. She has over 25 years of pharmaceutical experience working for both large and small pharmaceutical companies. Ms. Myers had served as Vice President Regulatory Affairs and Quality at Auxilium Pharmaceuticals, Inc. for 8 years prior to joining Malvern Consulting Group. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline in the QC and QA groups within the Biopharmaceutical R & D Division. She holds a BS in Biology from Neumann University.

Richard L. Sherman
Vice President, Strategic Partnering and Transactions
Mr. Sherman joined Malvern Consulting Group in 2011.  Mr. Sherman is also a Venture Partner with SCP focusing on the life sciences area. Prior to joining SCP, he spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline) and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm that is now a wholly-owned subsidiary of The Omnicom Group in New York.

Mr. Sherman has served on the Board of Directors of CytoMed, Inc., IBAH, Inc., Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., and Sparta Pharmaceuticals. He is Chairman of the Board of Biophage, Inc., and is a board member of the Sbarro Research Organization. He also serves as Secretary and General Counsel of Hawaii Biotech, Inc., acts as a consultant to the law firm of Goodsill Anderson Quinn & Stifel, and is a principal in CIP Capital, L.P.

He is on the Technology Advisory Board for The Children's Hospital of Philadelphia and is a member of the Advisory Board of the University of Hawaii Medical School.

Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. He received his J.D. from New York University School of Law in 1971 as a Root-Tilden Scholar.

Christopher T. Sharr
Vice President, Manufacturing
Mr. Sharr's current position is Vice President of Manufacturing for Malvern Consulting Group. Previously, he was Director, Manufacturing at Auxilium Pharmaceuticals, Inc., and was responsible for overall manufacturing, testing and distribution of the commercial product Testim® (1% testosterone gel). Mr. Sharr was also closely involved in the drug product development, manufacturing, clinical packaging and distribution of Xiaflex®. Prior to his experience at Auxilium, Mr. Sharr spent over 7 years working for IBAH Pharmaceutics, Inc., a contract research organization, which later became Omnicare Pharmaceutics, Inc. While at IBAH, he held positions of increasing responsibilities in the area of clinical manufacturing and packaging. Mr. Sharr has over 13 years experience related to the development and commercialization of chemical and biological drug products. Mr. Sharr holds a BS in Business Administration from Neumann University.

Christopher Barber
Director, Quality Assurance
Mr. Barber's current position is Director of Quality Assurance for Malvern Consulting Group. Previously, he was Quality Assurance Manager at Auxilium Pharmaceuticals, Inc., and was responsible for overall compliance of the commercial product Testim® (1% testosterone gel). Mr. Barber was also closely involved with the drug product development and preparation for commercialization of Xiaflex®. Prior to working at Auxilium he spent over 5 years working at GlaxoSmithKline holding positions of increasing responsibilities in the area of Quality Assurance and Quality Control. Mr. Barber has over 13 years quality and analytical experience related to the development and commercialization of chemical and biological drug products. He holds a BS in Biology: Microbiology from West Chester University.

Donna Nichols
Corporate Controller
Before joining Malvern Consulting Group, Ms. Nichols worked at Auxilium Pharmaceuticals as the Director of Accounting from July 2008-March 2009 and as Accounting Manager from February 2004-June 2008. She was the Director of Financial Reporting at Adolor Corporation from November 2000-June 2003 where she was part of the team that took the company through an IPO. She had worked for the company as a consultant from August 1996-November 2000. As a consultant, she was able to work with many different start -up companies. Prior to moving to Pennsylvania, she had worked for CPA firms in Maryland and New Jersey. Ms. Nichols received a B.S. degree from Rider University and is a Certified Public Accountant in Pennsylvania and Maryland.

Follow Us On


Recent News
Welcome to the new Malvern Consulting Group website.

Malvern Consulting Group 490 Lapp Road,
Malvern, PA 19355